Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)

被引：1

作者：

Highland, Kristin B. ^{[1
]}

Kuwana, Masataka ^{[2
]}

Azuma, Arata ^{[3
]}

Fischer, Aryeh ^{[4
]}

Maher, Toby M. ^{[5
,6
]}

Mayes, Maureen D. ^{[7
]}

Raghu, Ganesh ^{[8
]}

Girard, Mannaig ^{[9
]}

Kohlbrenner, Veronika ^{[10
]}

Clerisme-Beaty, Emmanuelle ^{[11
]}

Alves, Margarida ^{[11
]}

Distler, Oliver ^{[12
]}

机构：

[1] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA

[2] Nippon Med Sch, Dept Allergy & Rheumatol, Grad Sch Med, Tokyo, Japan

[3] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo, Japan

[4] Univ Colorado, Sch Med, Denver, CO USA

[5] Imperial Coll London, Natl Heart & Lung Inst, London, England

[6] Royal Brompton Hosp, Res Clin Res Facil, Natl Inst Hlth, London, England

[7] Univ Texas Houston, McGovern Med Sch, Div Rheumatol & Clin Immunogenet, Houston, TX USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Boehringer Ingelheim France SAS, Reims, France

[10] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[11] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[12] Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

D O I：

10.1183/13993003.congress-2019.PA4731

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA4731

引用

页数：2

共 50 条

[21] Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts
Kreuter, M.
Denton, C. P.
Ho, L. A.
Hoyles, R. K.
Glaspole, I.
Suda, T.
Miede, C.
Alves, M.
Maher, T. M.
EUROPEAN RESPIRATORY JOURNAL, 2022, 60
[22] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Glaeser, S.
Allanore, Y.
Vonk, M. C.
Azuma, A.
Mayes, M. D.
Gahlemann, M.
James, A.
Kohlbrenner, V
Stowasser, S.
Highland, K. B.
PNEUMOLOGIE, 2021, 75 : S26 - S27
[23] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Allanore, Yannick
Vonk, Madelon
Azuma, Arata
Mayes, Maureen
Gahlemann, Martina
James, Alexandra
Kohlbrenner, Veronika
Stowasser, Susanne
Highland, Kristin
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[24] GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL
Maher, Toby
Highland, Kristin
Gahlemann, Martina
Azuma, Arata
Fischer, Aryeh
Mayes, Maureen
Raghu, Ganesh
Sauter, Wiebke
Girard, Mannaig
Alves, Margarida
Clerisme-Beaty, Emmanuelle
Kohlbrenner, Veronika
Kuwana, Masataka
Distler, Oliver
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 831 - 832
[25] EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL
Allanore, Y.
Hoffmann-Vold, A. M.
Mayes, M.
Vonk, M.
Miede, C.
Alves, M.
Riemekasten, G.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 162 - 162
[26] EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND NORMAL VERSUS ELEVATED C-REACTIVE PROTEIN (CRP) AT BASELINE: ANALYSES FROM THE SENSCIS TRIAL
Riemekasten, G.
Carreira, P.
Saketkoo, L. A.
Aringer, M.
Chung, L.
Pope, J.
Miede, C.
Stowasser, S.
Gahlemann, M.
Alves, M.
Khanna, D.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 409 - 410
[27] Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and normal versus elevated C-reactive protein (CRP) at baseline: analyses from the SENSCIS trial
Markart, P.
Riemekasten, G.
Carreira, P. E.
Saketkoo, L. A.
Aringer, M.
Chung, L.
Pope, J.
Miede, C.
Stowasser, S.
Gahlemann, M.
Alves, M.
Khanna, D.
PNEUMOLOGIE, 2021, 75 : S28 - S29
[28] RISK OF MALNUTRITION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): FURTHER ANALYSES OF THE SENSCIS TRIAL
Volkmann, E.
Mcmahan, Z.
Johnson, S.
Smith, V.
Jouneau, S.
Miede, C.
Alves, M.
Herrick, A.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 674 - 674
[29] Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) beyond 52 weeks: data from the SENSCIS trial
Glaeser, S.
Maher, T. M.
Distler, O.
Allanore, Y.
Ogura, T.
Varga, J.
Vettori, S.
Crestani, B.
von Wangenheim, U.
Quaresma, M.
Alves, M.
Stowasser, S.
Assassi, S.
PNEUMOLOGIE, 2021, 75 : S28 - S28
[30] "EFFECTIVE LUNG AGE" IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL
Maher, T.
Bourdin, A.
Volkmann, E.
Vettori, S.
Distler, J. H. W.
Alves, M.
Stock, C.
Distler, O.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 447 - 447

← 1 2 3 4 5 →